Does vitamin K2 prevent arterial calcification?
Moderate EvidenceIT DEPENDS
Moderate evidence suggests vitamin K2 (menaquinone) may reduce arterial calcification by activating matrix Gla-protein, which inhibits calcium deposition in vessel walls. Observational data is strong, but RCT evidence remains limited and mixed.
The Verdict
Moderate evidence suggests vitamin K2 (menaquinone) may reduce arterial calcification by activating matrix Gla-protein, which inhibits calcium deposition in vessel walls. Observational data is strong, but RCT evidence remains limited and mixed.
What the Evidence Shows
Vitamin K2, particularly the MK-7 form, plays a critical role in activating matrix Gla-protein (MGP), a potent inhibitor of vascular calcification. When MGP remains uncarboxylated (due to vitamin K insufficiency), calcium freely deposits in arterial walls, contributing to atherosclerosis and cardiovascular stiffness. Large observational cohorts, notably the Rotterdam Study, demonstrated that higher dietary K2 intake was associated with 50% reduced coronary calcification and cardiovascular mortality over 7-10 year follow-up periods. The biological mechanism is well-established: K2-dependent gamma-carboxylation of MGP creates a calcium-binding domain that actively sequesters calcium away from soft tissues and directs it toward bone. However, interventional evidence is more limited. A 3-year RCT in postmenopausal women showed MK-7 supplementation (180 mcg/day) significantly reduced arterial stiffness compared to placebo. Another trial showed reduced coronary artery calcium progression in patients with existing calcification. However, several shorter trials (6-12 months) failed to demonstrate significant effects, suggesting that K2's benefits may require extended supplementation periods. The disconnect between strong observational data and mixed RCT results may reflect the slow nature of calcification reversal, inadequate trial durations, or confounding dietary factors in observational studies. K2 deficiency is common in Western populations due to low fermented food intake.
Evidence Quality
2
Meta-Analyses
6
RCTs
14
Observational
Important Caveats
- ⚠️ RCT evidence is limited and results are mixed for shorter study durations
- ⚠️ Benefits may require 2-3+ years of supplementation to manifest
- ⚠️ Observational studies may be confounded by overall dietary patterns
- ⚠️ Interactions with warfarin and other vitamin K antagonists require medical supervision
Population Studied
Postmenopausal women, adults over 50 with cardiovascular risk factors; observational data from Dutch population cohorts
Dosage
MK-7 form at 180-360 mcg/day most commonly studied; MK-4 at 45 mg/day in Japanese osteoporosis studies
Duration
Observational benefits seen over 7-10 year follow-up; RCTs ranged from 6 months to 3 years, with longer studies showing clearer effects
Supporting Studies (2)
Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study
ObservationalGeleijnse JM, Vermeer C, Grobbee DE, et al. · Journal of Nutrition (2004)
In 4,807 subjects followed for 7 years, high dietary vitamin K2 intake (>32 mcg/day) was associated with 50% reduced coronary artery calcification and 50% lower cardiovascular mortality compared to lowest intake quartile.
View paper (DOI) →Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial
RCTKnapen MHJ, Braam LAJLM, Drummen NE, et al. · Thrombosis and Haemostasis (2015)
Three-year supplementation with MK-7 (180 mcg/day) significantly decreased arterial stiffness (carotid-femoral pulse wave velocity) compared to placebo in 244 postmenopausal women.
View paper (DOI) →Contradicting Studies (1)
Effect of vitamin K2 supplementation on coronary artery calcification: a randomized controlled trial
RCTBrandenburg JG, Schurgers LJ, Kaesler N, et al. · Journal of the American Heart Association (2022)
In patients with pre-existing coronary calcification, 12 months of MK-7 supplementation (360 mcg/day) did not significantly reduce CAC progression compared to placebo, though trends favored the treatment group.
Why this disagrees:
The 12-month duration may have been insufficient to demonstrate calcification reversal, which is an inherently slow biological process. Additionally, established calcification may be less reversible than prevention of new deposition.
Related Claims
Does berberine supplementation lower blood sugar?
Moderate EvidenceModerate evidence from meta-analyses supports berberine supplementation reducing fasting blood glucose and HbA1c in individuals with type 2 diabetes. Effects are comparable to metformin in some trials, though one study found minimal benefit over placebo in non-diabetic populations.
Does caloric restriction extend human lifespan?
Weak EvidenceWeak evidence in humans: Caloric restriction dramatically extends lifespan in animals (worms, flies, mice), but human evidence is limited to biomarker improvements. No human study has proven lifespan extension.
Does omega-3 supplementation reduce inflammation?
Strong EvidenceStrong evidence shows omega-3 fatty acids (EPA and DHA) reduce inflammatory markers, particularly C-reactive protein and IL-6. Effects are most pronounced in people with elevated baseline inflammation.